Efavirenz-associated CNS disorders linked to CYP2B6 variant

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2005年 / 1035卷 / 1期
关键词：
Central Nervous System; Randomise Control Trial; Haas; Efavirenz; Trial Group;
D O I：
10.2165/00128415-200510350-00009
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5 / 5
相关论文
共 50 条
  • [31] CYP2B6☆6 is associated with increased breast cancer risk
    Justenhoven, Christina
    Pentimalli, Daniela
    Rabstein, Sylvia
    Harth, Volker
    Lotz, Anne
    Pesch, Beate
    Bruening, Thomas
    Doerk, Thilo
    Schuermann, Peter
    Bogdanova, Natalia
    Park-Simon, Tjoung-Won
    Couch, Fergus J.
    Olson, Janet E.
    Fasching, Peter A.
    Beckmann, Matthias W.
    Haeberle, Lothar
    Ekici, Arif
    Hall, Per
    Czene, Kamilla
    Liu, Janjun
    Li, Jingmei
    Baisch, Christian
    Hamann, Ute
    Ko, Yon-Dschun
    Brauch, Hiltrud
    INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (02) : 426 - 430
  • [32] CRYSTAL STRUCTURE OF CYP2B6 IN COMPLEX WITH AN EFAVIRENZ ANALOG: FROM PLASTICITY TO PI INTERACTIONS IN CYP2B ENZYMES
    Shah, Manish B.
    Halpert, James R.
    DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (01) : S32 - S33
  • [33] CYP2B6 18492T→C Polymorphism Compromises Efavirenz Concentration in Coinfected HIV and Tuberculosis Patients Carrying CYP2B6 Haplotype*1/*1
    Manosuthi, Weerawat
    Sukasem, Chonlaphat
    Thongyen, Supeda
    Nilkamhang, Samruay
    Manosuthi, Sukanya
    Sungkanuparph, Somnuek
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (04) : 2268 - 2273
  • [34] Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults
    Sukasem, Chonlaphat
    Cressey, Tim R.
    Prapaithong, Pattamawan
    Tawon, Yardpiroon
    Pasomsub, Ekawat
    Srichunrusami, Chutatip
    Jantararoungtong, Thawinee
    Lallement, Marc
    Chantratita, Wasun
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (06) : 1005 - 1012
  • [35] Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine
    Colic, Antoinette
    Alessandrini, Marco
    Pepper, Michael S.
    DRUG METABOLISM REVIEWS, 2015, 47 (02) : 111 - 123
  • [36] THE EXTENT OF INHIBITION AND INDUCTION OF CYP2B6 BY EFAVRIENZ IS CYP2B6 GENOTYPE-DEPENDENT
    Duong, A.
    Gufford, B.
    Masters, A.
    Burgess, K.
    Lu, J.
    Metzger, I.
    Desta, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S36 - S36
  • [37] Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series
    Park-Wyllie, LY
    Antoniou, T
    AIDS, 2003, 17 (04) : 638 - 640
  • [38] CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe
    Milcah Dhoro
    Simbarashe Zvada
    Bernard Ngara
    Charles Nhachi
    Gerald Kadzirange
    Prosper Chonzi
    Collen Masimirembwa
    BMC Pharmacology and Toxicology, 16
  • [39] CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe
    Dhoro, Milcah
    Zvada, Simbarashe
    Ngara, Bernard
    Nhachi, Charles
    Kadzirange, Gerald
    Chonzi, Prosper
    Masimirembwa, Collen
    BMC PHARMACOLOGY & TOXICOLOGY, 2015, 16
  • [40] CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana
    Gross, Robert
    Bellamy, Scarlett L.
    Ratshaa, Bakgaki
    Han, Xiaoyan
    Vujkovic, Marijana
    Aplenc, Richard
    Steenhoff, Andrew P.
    Mosepele, Mosepele
    Moorthy, Ganesh
    Zuppa, Athena F.
    Strom, Brian L.
    Bisson, Gregory P.
    AIDS, 2017, 31 (15) : 2107 - 2113
12345